Critically ill patients with cancer: A clinical perspective

Table 8 Main cardiovascular complications of oncological therapy[91,92]

Cardiovascular complications	Types	Oncological therapies
Left ventricular dysfunction	Cardiomyopathy or myocarditis	Anthracyclines (e.g., doxorubicin, aunorubicin, epirubicin, idarubicin), antiangiogenic agents (e.g., bevacisumab, sunitinib, sorafenib), alkylating agents (e.g., cyclophosphamide, cisplatin), monoclonal antibodies (e.g., trastuzumab, lapatinib), tyrosine kinase inhibitors (e.g., imatinib, dasatinib, nilotinib, sunitinib, sorafenib, lapatinib)
Arrhythmias	QT prolongation, bradycardia, heart block; Atrial arrhythmias; Ventricular arrhythmias or sudden cardiac death	Taxanes, arsenic trioxide, tyrosine kinase inhibitors (e.g., imatinib, dasatinib, nilotinib, sunitinib, sorafenib, lapatinib), anthracyclines(e.g., doxorubicin, aunorubicin, epirubicin, idarubicin)
Coronary artery disease	Acute coronary syndromes (included acute myocardial infarction); Chronic ischemic heart disease	Antimetabolites (e.g., gemcitabine, cytarabine), cisplatin, taxanes, thalidomide, bevacisumab, radiotherapy
Pericardial disease	Pericarditis (effusive or constrictive form)	Radiotherapy
Hypertension	New-onset or worsening	Vascular endothelial growth factor inhibitors, antiangiogenic agents (e.g., bevacisumab, sunitinib, sorafenib), cisplatin, interleukins, interferon